Purple Biotech Adds Novel TROP2 Antibody to CAPTN-3 Portfolio
Ticker: PPBT · Form: 6-K · Filed: Sep 3, 2025 · CIK: 1614744
Sentiment: neutral
Topics: pipeline-expansion, oncology, antibody
TL;DR
Purple Biotech just added a new TROP2 targeting antibody, IM1305, to their CAPTN-3 lineup.
AI Summary
On September 3, 2025, Purple Biotech Ltd. announced the expansion of its CAPTN-3 portfolio with the addition of IM1305, a novel tri-specific antibody. This new antibody targets TROP2, a protein commonly found in various solid tumors. The company previously operated under the names Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Why It Matters
The addition of IM1305 to the CAPTN-3 portfolio signifies Purple Biotech's strategic move to broaden its therapeutic offerings in oncology, potentially addressing unmet needs in TROP2-expressing cancers.
Risk Assessment
Risk Level: medium — Biotech companies often carry medium risk due to the inherent uncertainties in drug development and regulatory approval processes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- IM1305 (drug_candidate) — Novel tri-specific antibody
- CAPTN-3 (portfolio) — Expanded portfolio
- TROP2 (target) — Targeted protein
- Kitov Pharma Ltd. (company) — Former company name
- Kitov Pharmaceuticals Holdings Ltd. (company) — Former company name
- September 3, 2025 (date) — Date of press release
FAQ
What is the primary function of the newly added IM1305 antibody?
IM1305 is a novel tri-specific antibody designed to target TROP2.
Which portfolio is being expanded with the addition of IM1305?
The CAPTN-3 portfolio is being expanded with the addition of IM1305.
What is the significance of TROP2 as a target?
TROP2 is a protein that is commonly found in various solid tumors.
When was the press release announcing this expansion issued?
The press release was issued on September 3, 2025.
What were Purple Biotech Ltd.'s previous names?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-09-03 07:10:27
Filing Documents
- ea0255772-6k_purple.htm (6-K) — 9KB
- ea025577201ex99-1_purple.htm (EX-99.1) — 14KB
- 0001213900-25-083700.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 3, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2